---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-016082"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2022-06-28T23:59:59+00:00"
generated_at: "2026-06-24T22:32:30.507310+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Diffusion Pharma reports positive Altitude Trial results for TSC; appoints Raven Jaeger as CRO

## Summary
- TSC 2.5 mg/kg dose showed positive effects on pH (p<0.1 vs placebo) and lactate at end of exercise under simulated 15,000 ft hypoxia.
- Post-exercise recovery improved for pH, lactate, and oxygen saturation (SpO2) at 10 minutes with 2.5 mg/kg dose.
- TSC was safe and well tolerated with no serious adverse events across all doses.
- Results support planned Phase 2 Hypoxic Tumor Trial initiation in H2 2022; discussions with FDA ongoing.
- Employment agreement for CRO Raven Jaeger effective May 18, 2022 includes severance of 1.5x base salary + bonus upon change of control and 12-month non-compete.

## SEC filing metadata
- accession: 0001437749-22-016082
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2022-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774922016082/0001437749-22-016082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774922016082/dffn20220627_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-016082
- JSON: https://secwatch.observer/filing/0001437749-22-016082.json
- Plain text: https://secwatch.observer/filing/0001437749-22-016082.txt

## Key facts
- Executive change
  Raven Jaeger was appointed as Chief Regulatory Officer at CervoMed Inc..
  - Action: appointed
  - Role: Chief Regulatory Officer
  source text: As previously disclosed, on May 18, 2022, Raven Jaeger, M.S., was appointed as the Chief Regulatory Officer of Diffusion Pharmaceuticals Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774922016082/0001437749-22-016082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.